



## COVID-19 Vaccine Candidate Development

Guest Editors:

**Dr. Rafael Blasco**

Departamento de Biotecnología,  
INIA CSIC, Ctra. La Coruña km 7.5,  
E-28040 Madrid, Spain

**Dr. Javier Ortego**

Centro de Investigación en  
Sanidad Animal INIA CSIC,  
Valdeolmos-Alalpardo, Carretera  
de Algete a El Casar, Km 8, E-  
28040 Madrid, Spain

**Dr. Alejandro Marin-Lopez**

Department of Internal Medicine,  
Section of Infectious Diseases,  
School of Medicine, Yale  
University, New Haven, CT, USA

Deadline for manuscript  
submissions:

**closed (31 March 2023)**

### Message from the Guest Editors

Dear Colleagues,

In light of the considerable amount of work carried out in the field of vaccine technologies over the last years, much is to be learnt from the recent experiences of many research groups in vaccine design and testing, which may constitute a valuable resource for the future.

We are pleased to invite you to contribute to this Special Issue of *Vaccines*, entitled “COVID-19 vaccine candidate development”.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: COVID-19 candidate vaccine design, construction and trials, and refinements or innovations regarding vaccine testing, both in animal models and in human clinical trials.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)